DelveInsight’s, “Prurigo Nodularis Pipeline Insights 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prurigo Nodularis pipeline landscape. It covers the Prurigo Nodularis Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the Prurigo Nodularis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Prurigo Nodularis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Prurigo Nodularis Pipeline Outlook

Key Takeaways from the Prurigo Nodularis Marketed and Pipeline Drugs Report

• In May 2025, Incyte Corporation announced a study to evaluate the effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
• In May 2025, Amgen conducted a phase 3 study to assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects with Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies.
• DelveInsight’s Prurigo Nodularis Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Prurigo Nodularis treatment.
• The leading Prurigo Nodularis Companies such as Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho, and others.
• Promising Prurigo Nodularis Pipeline Therapies such as Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.

Stay ahead with the most recent pipeline outlook for Prurigo Nodularis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Prurigo Nodularis Treatment Drugs

Prurigo Nodularis Emerging Drugs Profile

• Nemolizumab: Chugai/Galderma

Nemolizumab was discovered by Chugai, and uses Chugai’s proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in blood. IL-31 has been identified as a pruritogenic cytokine, and reported to be associated with pruritus in many diseases including atopic dermatitis and hemodialysis. Nemolizumab is designed to inhibit the activities of IL-31 by competitively blocking binding with its receptor. It is currently in phase III stage of development.

• Nalbuphine ER: Trevi Therapeutics

Trevi is developing nalbuphine ER in a range of indications for which patients have few treatment options. With its dual mechanism of action, acting as both an antagonist (blocker) to the mu opioid receptor and as an agonist (activator) to the kappa opioid receptor, Nalbuphine ER has the potential to significantly improve the quality of life of patients suffering from serious neurologically mediated conditions by targeting the central and peripheral nervous systems. It is currently in phase III stage of development.

• Vixarelimab: Kiniksa Pharmaceuticals

Vixarelimab is Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMRβ). Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis. It is currently in phase II stage of development.

The Prurigo Nodularis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Prurigo Nodularis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prurigo Nodularis Treatment.
• Prurigo Nodularis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Prurigo Nodularis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement,s and financing details for future advancement of the Prurigo Nodularis market

Explore groundbreaking therapies and clinical trials in the Prurigo Nodularis Pipeline. Access DelveInsight’s detailed report now! @ New Prurigo Nodularis Drugs

Prurigo Nodularis Companies

Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.

Prurigo Nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Prurigo Nodularis Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Unveil the future of Prurigo Nodularis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Prurigo Nodularis Market Drivers and Barriers

Scope of the Prurigo Nodularis Pipeline Report

• Coverage- Global
• Prurigo Nodularis Companies- Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.
• Promising Prurigo Nodularis Pipeline Therapies- Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.
• Prurigo Nodularis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Prurigo Nodularis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Prurigo Nodularis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Prurigo Nodularis Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Prurigo Nodularis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Prurigo Nodularis – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Prurigo Nodularis Collaboration Deals
9. Late Stage Products (Phase III)
10. Nemolizumab: Chugai/Galderma
11. Nalbuphine ER: Trevi Therapeutics
12. Mid Stage Products (Phase II)
13. Vixarelimab: Kiniksa Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Pre-clinical and Discovery Stage Products
19. Drug Name: Company Name
20. Inactive Products
21. Prurigo Nodularis Key Companies
22. Prurigo Nodularis Key Products
23. Prurigo Nodularis- Unmet Needs
24. Prurigo Nodularis- Market Drivers and Barriers
25. Prurigo Nodularis- Future Perspectives and Conclusion
26. Prurigo Nodularis Analyst Views
27. Prurigo Nodularis Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight